Biohaven (BHVN) is back on investors’ radar after the company reported fresh R&D milestones, including first in human dosing of its PKM2 modulator BHV-8100 and early clinical data for degrader candidates BHV-1300 and BHV-1400.

Biohaven’s recent R&D updates around BHV-8100, BHV-1300, and BHV-1400 appear to be the key backdrop to a choppy share price pattern, with a 30 day share price return of 12.78% but a 1 year total shareholder return that has declined 34.86%, suggesting momentum is rebuilding from a lower base.

If this kind of pipeline driven story interests you, it can be useful to scan a wider set of healthcare related opportunities through the 39 healthcare AI stocks.

With Biohaven still loss making on zero reported revenue and trading on a rich pipeline premium, the key question is whether recent data justifies today’s valuation or if the stock already reflects much of its future growth potential.

Preferred Price to Book Multiple of 12.9x: Is It Justified?

Biohaven currently trades on a P/B of 12.9x, which looks stretched when set against both the US biotech industry and its closest listed peers.

P/B compares the company’s market value to its book value, essentially what investors are paying for each dollar of net assets. For a pre revenue, loss making biotech like Biohaven, a higher P/B often reflects how the market views the scientific pipeline, management track record, and potential future cash flows rather than current financials.

In Biohaven’s case, the 12.9x P/B stands well above the US biotech industry average of 2.3x and the peer average of 3.6x. That gap suggests investors are paying a sizeable premium for the company’s R&D portfolio, even though there is no reported revenue and the company remains unprofitable with a net loss of $647.677m and less than one year of cash runway.

For a numbers first view on how this premium stacks up against fundamentals, check out our valuation breakdown through the See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 12.9x (OVERVALUED)

However, investors still face clear risks around Biohaven’s continued net loss of $647.677m, its limited cash runway, and a fully clinical stage pipeline with no reported revenue.

Next Steps

With sentiment clearly split between concern and optimism, now is a good time to review the details for yourself and decide where you stand. To see the key issues on both sides of the argument, start with the 1 key reward and 5 important warning signs.

Looking for more investment ideas?

If Biohaven has sparked your interest, do not stop here. Broaden your watchlist now so you are not relying on a single stock story.

• Spot potential bargains early by scanning companies that combine quality with attractive valuations using the 47 high quality undervalued stocks.
• Build a sturdier core to your portfolio by focusing on companies with strong finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by tracking lesser known opportunities with solid fundamentals using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.